BEONE MEDICINES LTD-ADR (ONC) Fundamental Analysis & Valuation

NASDAQ:ONC • US07725L1026

Current stock price

282.36 USD
+6.67 (+2.42%)
Last:

This ONC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. ONC Profitability Analysis

1.1 Basic Checks

  • In the past year ONC was profitable.
  • ONC had a positive operating cash flow in the past year.
  • In the past 5 years ONC always reported negative net income.
  • ONC had a negative operating cash flow in each of the past 5 years.
ONC Yearly Net Income VS EBIT VS OCF VS FCFONC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -2B -4B -6B -8B -10B

1.2 Ratios

  • ONC has a Return On Assets of -0.28%. This is amongst the best in the industry. ONC outperforms 87.48% of its industry peers.
  • ONC has a better Return On Equity (-0.52%) than 89.21% of its industry peers.
  • With an excellent Return On Invested Capital value of 1.88%, ONC belongs to the best of the industry, outperforming 88.63% of the companies in the same industry.
Industry RankSector Rank
ROA -0.28%
ROE -0.52%
ROIC 1.88%
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ONC Yearly ROA, ROE, ROICONC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • ONC has a better Operating Margin (2.86%) than 88.25% of its industry peers.
  • ONC has a Gross Margin of 85.99%. This is amongst the best in the industry. ONC outperforms 88.05% of its industry peers.
  • ONC's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.86%
PM (TTM) N/A
GM 85.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
ONC Yearly Profit, Operating, Gross MarginsONC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ONC Health Analysis

2.1 Basic Checks

  • ONC has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • ONC has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ONC has been increased compared to 5 years ago.
  • The debt/assets ratio for ONC is higher compared to a year ago.
ONC Yearly Shares OutstandingONC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ONC Yearly Total Debt VS Total AssetsONC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

2.2 Solvency

  • ONC has an Altman-Z score of 4.75. This indicates that ONC is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.75, ONC is in the better half of the industry, outperforming 74.18% of the companies in the same industry.
  • The Debt to FCF ratio of ONC is 2.51, which is a good value as it means it would take ONC, 2.51 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of ONC (2.51) is better than 93.26% of its industry peers.
  • ONC has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
  • ONC's Debt to Equity ratio of 0.23 is on the low side compared to the rest of the industry. ONC is outperformed by 65.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF 2.51
Altman-Z 4.75
ROIC/WACC0.39
WACC4.77%
ONC Yearly LT Debt VS Equity VS FCFONC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10B -10B 20B 30B

2.3 Liquidity

  • ONC has a Current Ratio of 2.40. This indicates that ONC is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.40, ONC is not doing good in the industry: 71.48% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.17 indicates that ONC has no problem at all paying its short term obligations.
  • ONC's Quick ratio of 2.17 is on the low side compared to the rest of the industry. ONC is outperformed by 72.25% of its industry peers.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 2.17
ONC Yearly Current Assets VS Current LiabilitesONC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ONC Growth Analysis

3.1 Past

  • ONC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 381.02%, which is quite impressive.
  • The Revenue has grown by 56.19% in the past year. This is a very strong growth!
  • Measured over the past years, ONC shows a very strong growth in Revenue. The Revenue has been growing by 55.91% on average per year.
EPS 1Y (TTM)381.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-98.75%
Revenue 1Y (TTM)56.19%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%34.26%

3.2 Future

  • ONC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 96.91% yearly.
  • The Revenue is expected to grow by 18.35% on average over the next years. This is quite good.
EPS Next Y145.86%
EPS Next 2Y71.66%
EPS Next 3Y49.75%
EPS Next 5Y96.91%
Revenue Next Year41.02%
Revenue Next 2Y30.79%
Revenue Next 3Y25.12%
Revenue Next 5Y18.35%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ONC Yearly Revenue VS EstimatesONC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 20B 40B 60B 80B
ONC Yearly EPS VS EstimatesONC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1K 2K

More info and screens

Find the best growth stocksShow best growing peers

6

4. ONC Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 13.73, the valuation of ONC can be described as correct.
  • Compared to the rest of the industry, the Price/Earnings ratio of ONC indicates a rather cheap valuation: ONC is cheaper than 95.76% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of ONC to the average of the S&P500 Index (25.50), we can say ONC is valued slightly cheaper.
  • A Price/Forward Earnings ratio of 40.74 indicates a quite expensive valuation of ONC.
  • Based on the Price/Forward Earnings ratio, ONC is valued cheaper than 90.94% of the companies in the same industry.
  • ONC is valuated expensively when we compare the Price/Forward Earnings ratio to 22.67, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 13.73
Fwd PE 40.74
ONC Price Earnings VS Forward Price EarningsONC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, ONC is valued cheaper than 91.91% of the companies in the same industry.
Industry RankSector Rank
P/FCF 64.9
EV/EBITDA N/A
ONC Per share dataONC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • ONC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as ONC's earnings are expected to grow with 49.75% in the coming years.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y71.66%
EPS Next 3Y49.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ONC Dividend Analysis

5.1 Amount

  • No dividends for ONC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ONC Fundamentals: All Metrics, Ratios and Statistics

BEONE MEDICINES LTD-ADR

NASDAQ:ONC (3/25/2026, 2:07:34 PM)

282.36

+6.67 (+2.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-07
Inst Owners41%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change7.11%
Market Cap31.25B
Revenue(TTM)27.21B
Net Income(TTM)-153.00M
Analysts82.67
Price Target365.13 (29.31%)
Short Float %18.44%
Short Ratio5.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.56
Dividend Growth(5Y)N/A
DP-360.44%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)590.84%
Min EPS beat(2)-5.45%
Max EPS beat(2)1187.13%
EPS beat(4)3
Avg EPS beat(4)1523.03%
Min EPS beat(4)-5.45%
Max EPS beat(4)3109.85%
EPS beat(8)3
Avg EPS beat(8)516.07%
EPS beat(12)4
Avg EPS beat(12)343.82%
EPS beat(16)5
Avg EPS beat(16)253.79%
Revenue beat(2)1
Avg Revenue beat(2)2.46%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)6.29%
Revenue beat(4)2
Avg Revenue beat(4)2.29%
Min Revenue beat(4)-1.36%
Max Revenue beat(4)6.29%
Revenue beat(8)6
Avg Revenue beat(8)8.35%
Revenue beat(12)10
Avg Revenue beat(12)12.39%
Revenue beat(16)13
Avg Revenue beat(16)10.75%
PT rev (1m)0%
PT rev (3m)4.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.89%
EPS NY rev (1m)-1.82%
EPS NY rev (3m)17.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.71%
Revenue NY rev (3m)-0.22%
Valuation
Industry RankSector Rank
PE 13.73
Fwd PE 40.74
P/S 6.04
P/FCF 64.9
P/OCF 44.28
P/B 7.34
P/tB 7.67
EV/EBITDA N/A
EPS(TTM)20.57
EY7.29%
EPS(NY)6.93
Fwd EY2.45%
FCF(TTM)4.35
FCFY1.54%
OCF(TTM)6.38
OCFY2.26%
SpS46.77
BVpS38.46
TBVpS36.84
PEG (NY)0.09
PEG (5Y)N/A
Graham Number133.41
Profitability
Industry RankSector Rank
ROA -0.28%
ROE -0.52%
ROCE 2.73%
ROIC 1.88%
ROICexc 5.89%
ROICexgc 6.47%
OM 2.86%
PM (TTM) N/A
GM 85.99%
FCFM 9.3%
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
F-Score7
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF 2.51
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 4.33%
Interest Coverage 250
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.4
Quick Ratio 2.17
Altman-Z 4.75
F-Score7
WACC4.77%
ROIC/WACC0.39
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)20.18%
Cap/Sales(5y)27.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)381.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-98.75%
EPS Next Y145.86%
EPS Next 2Y71.66%
EPS Next 3Y49.75%
EPS Next 5Y96.91%
Revenue 1Y (TTM)56.19%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%34.26%
Revenue Next Year41.02%
Revenue Next 2Y30.79%
Revenue Next 3Y25.12%
Revenue Next 5Y18.35%
EBIT growth 1Y115.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year208.45%
EBIT Next 3Y66.24%
EBIT Next 5Y54.47%
FCF growth 1Y131.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y172.14%
OCF growth 3YN/A
OCF growth 5YN/A

BEONE MEDICINES LTD-ADR / ONC Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BEONE MEDICINES LTD-ADR (ONC) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ONC.


What is the valuation status for ONC stock?

ChartMill assigns a valuation rating of 6 / 10 to BEONE MEDICINES LTD-ADR (ONC). This can be considered as Fairly Valued.


How profitable is BEONE MEDICINES LTD-ADR (ONC) stock?

BEONE MEDICINES LTD-ADR (ONC) has a profitability rating of 5 / 10.


Can you provide the PE and PB ratios for ONC stock?

The Price/Earnings (PE) ratio for BEONE MEDICINES LTD-ADR (ONC) is 13.73 and the Price/Book (PB) ratio is 7.34.


Can you provide the dividend sustainability for ONC stock?

The dividend rating of BEONE MEDICINES LTD-ADR (ONC) is 0 / 10 and the dividend payout ratio is -360.44%.